Clinical Trial Update: Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating patisiran in hereditary transthyretin-mediated amyloidosis patients with disease progression after liver transplant has completed with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Amyloidosis
• Transthyretin Amyloidosis

Drugs mentioned

• Patisiran (patisiran)

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: Amyloidosis, Familial, Transthyretin Amyloidosis | Phase 3 | Status: COMPLETED | Results posted: 2021-12-21